Trial Outcomes & Findings for A Study for the Treatment of Alcohol Dependence (NCT NCT00804570)
NCT ID: NCT00804570
Last Updated: 2019-09-24
Results Overview
The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of heavy drinking days. Heavy drinking is defined as ≥4 drinks/day for women and ≥5 drinks/day for men. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.
COMPLETED
PHASE2
375 participants
Week 16
2019-09-24
Participant Flow
Participant milestones
| Measure |
LY2196044
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
once daily, orally, 16 weeks
|
|---|---|---|
|
Overall Study
STARTED
|
187
|
188
|
|
Overall Study
COMPLETED
|
115
|
94
|
|
Overall Study
NOT COMPLETED
|
72
|
94
|
Reasons for withdrawal
| Measure |
LY2196044
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
once daily, orally, 16 weeks
|
|---|---|---|
|
Overall Study
Adverse Event
|
14
|
7
|
|
Overall Study
Lack of Efficacy
|
0
|
1
|
|
Overall Study
Lost to Follow-up
|
18
|
21
|
|
Overall Study
Entry criteria not met
|
5
|
5
|
|
Overall Study
Protocol Violation
|
12
|
16
|
|
Overall Study
Physician Decision
|
1
|
2
|
|
Overall Study
Sponsor decision
|
1
|
4
|
|
Overall Study
Withdrawal by Subject
|
21
|
38
|
Baseline Characteristics
A Study for the Treatment of Alcohol Dependence
Baseline characteristics by cohort
| Measure |
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=188 Participants
once daily, orally, 16 weeks
|
Total
n=375 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
44.92 years
STANDARD_DEVIATION 10.62 • n=99 Participants
|
44.79 years
STANDARD_DEVIATION 10.08 • n=107 Participants
|
44.85 years
STANDARD_DEVIATION 10.34 • n=206 Participants
|
|
Sex: Female, Male
Female
|
66 Participants
n=99 Participants
|
66 Participants
n=107 Participants
|
132 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
121 Participants
n=99 Participants
|
122 Participants
n=107 Participants
|
243 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
White
|
152 participants
n=99 Participants
|
134 participants
n=107 Participants
|
286 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
26 participants
n=99 Participants
|
43 participants
n=107 Participants
|
69 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Asian
|
1 participants
n=99 Participants
|
1 participants
n=107 Participants
|
2 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
0 participants
n=99 Participants
|
3 participants
n=107 Participants
|
3 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Multiple races
|
7 participants
n=99 Participants
|
7 participants
n=107 Participants
|
14 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Unknown/Missing
|
1 participants
n=99 Participants
|
0 participants
n=107 Participants
|
1 participants
n=206 Participants
|
|
Region of Enrollment
United States
|
187 participants
n=99 Participants
|
188 participants
n=107 Participants
|
375 participants
n=206 Participants
|
|
Years of Alcohol Use
|
30.64 years
STANDARD_DEVIATION 9.50 • n=99 Participants
|
28.60 years
STANDARD_DEVIATION 10.44 • n=107 Participants
|
29.53 years
STANDARD_DEVIATION 10.02 • n=206 Participants
|
|
Years of Heavy Drinking
|
25.06 years
STANDARD_DEVIATION 13.20 • n=99 Participants
|
24.83 years
STANDARD_DEVIATION 11.00 • n=107 Participants
|
24.94 years
STANDARD_DEVIATION 12.05 • n=206 Participants
|
PRIMARY outcome
Timeframe: Week 16Population: Participants with a baseline and post-baseline value.
The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of heavy drinking days. Heavy drinking is defined as ≥4 drinks/day for women and ≥5 drinks/day for men. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=181 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=172 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Percentage of Heavy Drinking Days at Week 16 Endpoint
|
-43.02 percentage of days
Standard Error 2.09
|
-38.72 percentage of days
Standard Error 2.12
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of drinks consumed per day. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=185 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=179 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Drinks Per Day at Week 16 Endpoint
|
-5.37 number of drinks/day
Standard Error 0.22
|
-4.66 number of drinks/day
Standard Error 0.22
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the percentage of days abstinent. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=181 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=172 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Percentage of Days Abstinent at Week 16 Endpoint
|
33.49 percentage of days
Standard Error 2.05
|
28.12 percentage of days
Standard Error 2.09
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of drinks consumed on the days the participant drank. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=182 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=178 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Drinks Per Drinking Day at Week 16 Endpoint
|
-3.77 number of drinks/drinking day
Standard Error 0.26
|
-3.38 number of drinks/drinking day
Standard Error 0.26
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of drinks consumed on heavy drinking days. Heavy drinking is defined as ≥4 drinks/day for women and ≥5 drinks/day for men. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=178 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=175 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Drinks Per Heavy Drinking Day at Week 16 Endpoint
|
-2.61 number of drinks/heavy drinking day
Standard Error 0.26
|
-2.17 number of drinks/heavy drinking day
Standard Error 0.26
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
Cravings will be assessed using the OCDS. The OCDS is a 14-item self-rating instrument. Total scores range from 0-40. Higher scores indicate more obsessive and craving. Least Squares (LS) Mean value was controlled for treatment, site, visit, gender, history, baseline, gender\*history, treatment\*visit, baseline\*visit, gender\*treatment, gender\*treatment\*visit. Subject was treated as a random effect. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=174 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=162 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Obsessive Compulsive Drinking Scale (OCDS) Total Score at Week 16 Endpoint
|
-8.64 units on a scale
Standard Error 0.51
|
-7.96 units on a scale
Standard Error 0.53
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
DrInC is a self-administered, 50-item questionnaire designed to measure adverse consequences of alcohol abuse in 5 areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. DrInC-2R provides a measurement since the last interview. Total scores range from 0-150, and higher scores indicate greater severity of symptoms. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. Subject was treated as a random effect. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=148 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=136 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Drinker Inventory of Consequences (DrInC) - Recent Consequences (DrInC-2R) Total Score at Week 16 Endpoint
|
-16.54 units on a scale
Standard Error 1.09
|
-13.53 units on a scale
Standard Error 1.11
|
SECONDARY outcome
Timeframe: Week 16Population: Participants with a baseline and post-baseline value.
GGT and carbohydrate-deficient transferrin (%CDT) will be used as biochemical markers of alcohol consumption. A combination of GGT and %CDT improves the sensitivity of detecting excessive alcohol consumption as compared to either marker alone, or other traditional markers. Elevated levels indicate heavy alcoholism. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=176 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=161 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Ratio of Geometric Means Over Baseline in Gamma-Glutamyltransferase (GGT) Level at Week 16 Endpoint
|
0.85 ratio
Standard Error 0.02
|
0.94 ratio
Standard Error 0.02
|
SECONDARY outcome
Timeframe: Week 16Population: Participants with a baseline and post-baseline value.
Gamma-Glutamyltransferase (GGT) and %CDT will be used as biochemical markers of alcohol consumption. A combination of GGT and %CDT improves the sensitivity of detecting excessive alcohol consumption as compared to either marker alone, or other traditional markers. Elevated levels indicate heavy alcoholism. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=173 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=157 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Ratio of Geometric Means Over Baseline in Percent Carbohydrate-Deficient Transferrin (%CDT) Level at Week 16 Endpoint
|
0.90 ratio
Standard Error 0.02
|
0.94 ratio
Standard Error 0.02
|
SECONDARY outcome
Timeframe: Week 16Population: Participants with a baseline and post-baseline value.
AST is a potential biomarker for LY2196044 efficacy as decreases reflect decreased alcohol consumption. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=176 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=161 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Ratio of Geometric Means Over Baseline in Aspartate Transaminase (AST) Level at Week 16 Endpoint
|
0.88 ratio
Standard Error 0.02
|
0.94 ratio
Standard Error 0.02
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
The BDI-II contains 21 items that characterize how the subject was feeling in the past 2 weeks. There is a 4-point scale for each item ranging from 0 to 3 (0=no depression; 3=very depressed). Total scores range from 0-63. Higher scores indicate greater severity of depression. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=185 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=179 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Beck Depression Inventory II (BDI-II) Total Score at Week 16 Endpoint
|
-3.10 units on a scale
Standard Error 0.28
|
-2.78 units on a scale
Standard Error 0.28
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
BAI is a 21-item patient-completed questionnaire designed to assess the characteristics of anxiety. Participant was asked to rate how much he or she has been bothered by each symptom over the past week. Each item is rated on a 4-point scale (0=not present; 3=present in the extreme). Total scores range from 0 to 63. The higher the score, the more severe the anxiety symptoms. LS Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=150 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=136 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Beck Anxiety Inventory (BAI) Total Score at Week 16 Endpoint
|
-1.98 units on a scale
Standard Error 0.25
|
-1.54 units on a scale
Standard Error 0.26
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
The BIS-11 is a 30-item, self-administered impulsivity scale. Motor, cognitive, and non-planning domains are assessed and a total score is computed. This scale has previously been used in substance-abusing populations. Total scores range from 30-120. Higher scores indicate greater severity of symptoms. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, baseline, gender\*family history.
Outcome measures
| Measure |
LY2196044
n=120 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=99 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Barratt Impulsivity Scale-11 (BIS-11) Total Score at Week 16 Endpoint
|
-1.70 units on a scale
Standard Error 0.65
|
-2.95 units on a scale
Standard Error 0.69
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
Thoughts About Abstinence Scale was to measure participant's commitment to abstinence. It includes 3 items on a scale of 1-10: own desire to stop drinking (1=no desire to quit); own expectation of success in quitting (1=lowest expectation of success); how difficult to quit and remain abstinent (1=lowest amount of difficulty); and their goal related to alcohol use (scale of 1-7: 1=having no goal, up to total abstinence at 6 \[7 was none of 6 above\]). Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, baseline, gender\*family history.
Outcome measures
| Measure |
LY2196044
n=123 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=100 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Desire to stop drinking at this time
|
-0.60 units on a scale
Standard Error 0.20
|
-0.11 units on a scale
Standard Error 0.21
|
|
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Expectation of success in quitting alcohol
|
-0.20 units on a scale
Standard Error 0.25
|
-0.00 units on a scale
Standard Error 0.27
|
|
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Difficulty to quit and remain abstinent
|
-1.11 units on a scale
Standard Error 0.28
|
-0.63 units on a scale
Standard Error 0.30
|
|
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Goal related to alcohol use
|
0.00 units on a scale
Standard Error 0.17
|
0.04 units on a scale
Standard Error 0.18
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
Q-LES-Q-SF is a self-report instrument that assesses the degree of enjoyment and satisfaction in daily life activities. The domains include: social relationships, living or house situation, and physical health. Total scores range from 14-70. Higher scores indicate better quality of life. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=150 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=133 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Total Score at Week 16 Endpoint
|
2.85 units on a scale
Standard Error 0.56
|
2.08 units on a scale
Standard Error 0.59
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
EWPS is a self-rated work productivity scale that assesses such topics as work hours, work missed, and behaviors and feelings related to the workplace. The EWPS will be completed only by subjects who work outside the home. There are 25 items and total scores range from 0-100. Higher scores indicate poorer productivity. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=119 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=106 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at Week 16 Endpoint
|
-5.67 units on a scale
Standard Error 0.76
|
-6.13 units on a scale
Standard Error 0.79
|
SECONDARY outcome
Timeframe: Over 16 weeksPopulation: Participants who took study drug and contributed PK sample.
Plasma concentrations were analyzed using population PK methodology with non-linear mixed effect modeling (NONMEM) software.
Outcome measures
| Measure |
LY2196044
n=169 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
once daily, orally, 16 weeks
|
|---|---|---|
|
Population Pharmacokinetic (PK) - Apparent Clearance
|
36.5 Liter/hour (L/hr)
Standard Error 3.97
|
—
|
SECONDARY outcome
Timeframe: Over 16 weeksPopulation: Participants who took study drug and contributed PK sample.
Plasma concentrations were analyzed using population PK methodology with non-linear mixed effect modeling (NONMEM) software.
Outcome measures
| Measure |
LY2196044
n=169 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
once daily, orally, 16 weeks
|
|---|---|---|
|
Population Pharmacokinetic (PK) - Apparent Volume of Distribution
|
587 Liter (L)
Standard Error 8.38
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants who took at least one dose of study drug.
Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=179 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Supine Blood Pressure (BP) at Week 16 Endpoint
Supine Systolic BP
|
-1.22 millimeters of mercury (mmHg)
Standard Error 0.68
|
-0.45 millimeters of mercury (mmHg)
Standard Error 0.69
|
|
Change From Baseline in Supine Blood Pressure (BP) at Week 16 Endpoint
Supine Diastolic BP
|
-1.53 millimeters of mercury (mmHg)
Standard Error 0.43
|
-1.08 millimeters of mercury (mmHg)
Standard Error 0.44
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants who took at least one dose of study drug.
Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=179 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Supine Pulse Rate at Week 16 Endpoint
|
-0.16 beats per minute (bpm)
Standard Error 0.51
|
0.37 beats per minute (bpm)
Standard Error 0.53
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants who took at least one dose of study drug.
Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=148 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=135 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in QTc Fridericia's Correction Interval (QTcF) Measured by Electrocardiograms at Week 16 Endpoint
|
-1.90 milliseconds
Standard Error 0.86
|
0.18 milliseconds
Standard Error 0.90
|
SECONDARY outcome
Timeframe: Baseline through Week 16Population: Participants who took at least one dose of study drug.
Percentage of participants discontinued study due to one or more AEs.
Outcome measures
| Measure |
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=188 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Percentage of Participants Discontinuation Due to Adverse Events (AEs)
|
7.5 percentage of participants
|
3.7 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline through Week 16Population: Participants who took at least one dose of study drug.
Percentage of participants had one or more TEAEs during treatment period. TEAE is a worsening or new occurrence of adverse event during treatment compared to baseline.
Outcome measures
| Measure |
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=188 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)
|
76.5 percentage of participants
|
61.7 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Week 16Orthostatic BP is the BP measured within 3 minutes of standing. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=179 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Orthostatic Blood Pressure (BP) at Week 16 Endpoint
Orthostatic Diastolic BP
|
-0.07 mmHg
Standard Error 0.27
|
0.25 mmHg
Standard Error 0.28
|
|
Change From Baseline in Orthostatic Blood Pressure (BP) at Week 16 Endpoint
Orthostatic Systolic BP
|
-1.23 mmHg
Standard Error 0.42
|
-0.55 mmHg
Standard Error 0.43
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants who took at least one dose of study drug.
Orthostatic pulse rate is the pulse rate measured within 3 minutes of standing. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=179 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Orthostatic Pulse Rate at Week 16 Endpoint
|
0.65 beats per minute
Standard Error 0.30
|
-0.09 beats per minute
Standard Error 0.31
|
SECONDARY outcome
Timeframe: Baseline through Week 16Population: Participants who took at least one dose of study drug.
The revised CIWA-Ar scale measured the severity of alcohol withdrawal by rating 10 signs and symptoms: nausea; tremor; autonomic hyperactivity; anxiety; agitation; tactile, visual, and auditory disturbances; headache; and disorientation. Total scores range from 0-67. Higher scores indicate greater severity of withdrawal.
Outcome measures
| Measure |
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=188 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Number of Participants With Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)≥10 at Any Time From Baseline Through Week 16 Endpoint
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Baseline, Week 16Population: Participants with a baseline and post-baseline value.
The GSRS is a clinician-administered scale used to assess upper and lower gastrointestinal physical symptoms. 15 items covering domains of abdominal pain, reflux syndrome, indigestion syndrome, diarrhea syndrome, and constipation syndrome were assessed with a 1-week recall period. Total scores range from 0-45. Higher scores indicate greater severity of symptoms. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.
Outcome measures
| Measure |
LY2196044
n=185 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
|
Placebo
n=179 Participants
once daily, orally, 16 weeks
|
|---|---|---|
|
Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Total Score at Week 16 Endpoint
|
0.03 units on a scale
Standard Error 0.13
|
-0.54 units on a scale
Standard Error 0.13
|
Adverse Events
LY2196044
Placebo
Serious adverse events
| Measure |
LY2196044
n=187 participants at risk
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily (QD), orally (PO), 16 weeks
|
Placebo
n=188 participants at risk
once daily (QD), orally (PO), 16 weeks
|
|---|---|---|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.53%
1/187 • Number of events 1
|
0.00%
0/188
|
|
Hepatobiliary disorders
Biliary colic
|
0.53%
1/187 • Number of events 1
|
0.00%
0/188
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/187
|
0.53%
1/188 • Number of events 1
|
|
Infections and infestations
Appendicitis
|
0.53%
1/187 • Number of events 1
|
0.00%
0/188
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/187
|
0.53%
1/188 • Number of events 1
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/187
|
0.53%
1/188 • Number of events 1
|
|
Investigations
Blood creatine phosphokinase mb increased
|
0.00%
0/187
|
0.53%
1/188 • Number of events 1
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/187
|
0.53%
1/188 • Number of events 1
|
|
Psychiatric disorders
Alcoholism
|
0.00%
0/187
|
0.53%
1/188 • Number of events 1
|
|
Psychiatric disorders
Depression
|
0.00%
0/187
|
0.53%
1/188 • Number of events 1
|
|
Surgical and medical procedures
Alcohol detoxification
|
0.53%
1/187 • Number of events 1
|
0.00%
0/188
|
Other adverse events
| Measure |
LY2196044
n=187 participants at risk
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily (QD), orally (PO), 16 weeks
|
Placebo
n=188 participants at risk
once daily (QD), orally (PO), 16 weeks
|
|---|---|---|
|
Gastrointestinal disorders
Abdominal distension
|
6.4%
12/187 • Number of events 12
|
1.1%
2/188 • Number of events 2
|
|
Gastrointestinal disorders
Abdominal pain
|
10.2%
19/187 • Number of events 22
|
3.2%
6/188 • Number of events 6
|
|
Gastrointestinal disorders
Abdominal pain upper
|
5.9%
11/187 • Number of events 13
|
1.6%
3/188 • Number of events 4
|
|
Gastrointestinal disorders
Constipation
|
6.4%
12/187 • Number of events 13
|
1.6%
3/188 • Number of events 5
|
|
Gastrointestinal disorders
Diarrhoea
|
19.3%
36/187 • Number of events 39
|
8.5%
16/188 • Number of events 17
|
|
Gastrointestinal disorders
Dyspepsia
|
3.2%
6/187 • Number of events 6
|
5.3%
10/188 • Number of events 11
|
|
Gastrointestinal disorders
Flatulence
|
9.1%
17/187 • Number of events 17
|
4.8%
9/188 • Number of events 9
|
|
Gastrointestinal disorders
Frequent bowel movements
|
4.3%
8/187 • Number of events 8
|
0.53%
1/188 • Number of events 1
|
|
Gastrointestinal disorders
Gastrointestinal sounds abnormal
|
3.7%
7/187 • Number of events 8
|
1.6%
3/188 • Number of events 3
|
|
Gastrointestinal disorders
Nausea
|
13.4%
25/187 • Number of events 28
|
6.4%
12/188 • Number of events 12
|
|
Gastrointestinal disorders
Vomiting
|
5.9%
11/187 • Number of events 11
|
1.6%
3/188 • Number of events 3
|
|
General disorders
Fatigue
|
9.1%
17/187 • Number of events 20
|
4.8%
9/188 • Number of events 9
|
|
Infections and infestations
Upper respiratory tract infection
|
5.3%
10/187 • Number of events 11
|
3.7%
7/188 • Number of events 7
|
|
Investigations
Blood creatine phosphokinase increased
|
2.1%
4/187 • Number of events 4
|
3.2%
6/188 • Number of events 9
|
|
Metabolism and nutrition disorders
Decreased appetite
|
4.8%
9/187 • Number of events 10
|
2.7%
5/188 • Number of events 5
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
1.1%
2/187 • Number of events 2
|
3.7%
7/188 • Number of events 7
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
4.8%
9/187 • Number of events 9
|
3.7%
7/188 • Number of events 10
|
|
Nervous system disorders
Headache
|
5.9%
11/187 • Number of events 17
|
9.0%
17/188 • Number of events 20
|
|
Nervous system disorders
Somnolence
|
3.2%
6/187 • Number of events 6
|
1.1%
2/188 • Number of events 2
|
|
Psychiatric disorders
Anxiety
|
3.2%
6/187 • Number of events 7
|
1.1%
2/188 • Number of events 2
|
|
Psychiatric disorders
Libido decreased
|
3.2%
6/187 • Number of events 6
|
0.53%
1/188 • Number of events 1
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
3.2%
6/187 • Number of events 6
|
0.53%
1/188 • Number of events 1
|
|
Vascular disorders
Hypertension
|
3.2%
6/187 • Number of events 6
|
1.6%
3/188 • Number of events 3
|
Additional Information
Chief Medical Officer
Eli Lilly and Company
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60